Fisher Paykel Healthcare (FPY) is out with an update to the market in FY24. It upgraded its earnings guidance for the financial year to be in the range of approximately between $260M (NZD) and $265M (NZD), higher than the previous prediction of $250M and $260M. Chief Executive, Lewis Gradon, says that "in the hospital product group there has been a continuation of solid demand for our hospital consumables across the product portfolio throughout the second half, which is towards the upper end of our expectations from November." Our experts, Jun Bei Liu from Tribeca Investment Partners and Adam Dawes from Shaw and Partners, shared their views on the company. Jun Bei says that the announcement is positive and that the worst is now past for them, but she says its "super expensive" and would rather be in other healthcare stocks. Adam agrees with Jun Bei and flags that there are some property valuations that are due to come through in the next quarter and could change things in relation to the recent upgrade. So will it be a buy, hold or sell?
Watch the full episode here: [ Ссылка ]
Stocks covered:
CAR Car group
SUL Super Retail Group
EDV Endeavour
TYR Tyro
PBH Pointsbet
HLO Helloworld
WEB Webjet
ALL Aristocrat Leisure
NWSNews Corp
COH Cochlear
Trade your Stock of the Day with IG: [ Ссылка ]
Subscribe to ausbiz:
the COB newsletter - [ Ссылка ]
ausbiz channel - [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
#asx #sharemarket #stocks #ausbiz #shares #investing #equities #hotstocks #stockpicking
